Developing an Injectable Compound for a Dual- Chamber Delivery System

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-05-15-2017
Volume 2017 eBook
Issue 1
Pages: s28-s30

Prefilled dual-chamber cartridges offer several advantages. Several steps should be taken to determine if a dual-chamber system is viable for a lyophilized injectable drug product.

As global demand for injectable systems grows, so too does the demand for innovative delivery options beyond the traditional system of syringe and vial. For lyophilized forms, dual-chamber systems offer advantages.

When considering whether to use a dual-chamber system, it is important to understand the necessary development process.

Download

Pharmaceutical Technology’s 2017 Biologics and Sterile Drug Manufacturing eBook

.

 

 

 

Articles in this issue
SGS-Article_225.jpg
Clean, Disinfect, and Validate
Bioburden_225-1.jpg
Kill the Bioburden, Not the Biological Indicator
Cryoport_225.jpg
Cold Chain Logistics for Personalized Medicine: Dealing With Complexity
RawMaterials_225.jpg
Ensuring the Biological Integrity of Raw Materials
TechTransfer_225.jpg
Getting Biopharmaceutical Tech Transfer Right the First Time
Vetter_225.jpg
Developing an Injectable Compound for a Dual- Chamber Delivery System
GSK_225.jpg
Case Study: Retrofitting Two New High-Purity Water Systems
SUBioreactors_225.jpg
Single-Use Bioreactors Have Reached the Big Time
ParallelProcessing_225.jpg
Parallel Processing
Biosims_225.jpg
Cost Considerations Drive Lean Technology in Biomanufacturing
Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Related Content
TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

FDA CBER Director Peter Marks Resigns

Susan Haigney
March 31st 2025
Article

Marks called out an ‘assault’ on truth and science in his resignation letter, which has sent the bio/pharmaceutical industry reeling.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

TOP NEWS on grunge world map | Image Credit: © Sean K - stock.adobe.com

BIO Survey: Tariffs May Reduce Access, Delay Innovation, Create Red Tape

Patrick Lavery
March 27th 2025
Article

The Biotechnology Innovation Organization’s new membership survey said that 90% of US biotech companies rely on imported components for at least half of their FDA-approved products.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Benuvia Awarded NIH Contract for GMP Synthesis of Psilocybin, Other Drug Substances

Patrick Lavery
March 25th 2025
Article

The contract will support R&D of high-quality APIs for substance use disorders and mental health conditions, starting with synthesis and scale-up of psilocybin, which is derived from mushrooms.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

AstraZeneca and Alteogen Sign License Agreement for Developing Subcutaneous Formulations of Oncology Assets

Feliza Mirasol
March 25th 2025
Article

Under the agreement, AstraZeneca will use Alteogen’s proprietary hyaluronidase platform technology to develop and commercialize subcutaneous formulations of multiple oncology assets in its portfolio.